Imai T - Search Results

1

Exclusive increase of CX3CR1+CD28-CD4+ T cells in inflammatory bowel disease and their recruitment as intraepithelial lymphocytes.

Kobayashi T, Okamoto S, Iwakami Y, Nakazawa A, Hisamatsu T, Chinen H, Kamada N, Imai T, Goto H, Hibi T. Kobayashi T, et al. Among authors: imai t. Inflamm Bowel Dis. 2007 Jul;13(7):837-46. doi: 10.1002/ibd.20113. Inflamm Bowel Dis. 2007. PMID: 17285595

2

Migration of CX3CR1-positive T cells producing type 1 cytokines and cytotoxic molecules into the synovium of patients with rheumatoid arthritis.

Nanki T, Imai T, Nagasaka K, Urasaki Y, Nonomura Y, Taniguchi K, Hayashida K, Hasegawa J, Yoshie O, Miyasaka N. Nanki T, et al. Among authors: imai t. Arthritis Rheum. 2002 Nov;46(11):2878-83. doi: 10.1002/art.10622. Arthritis Rheum. 2002. PMID: 12428227 Free article.

3

Inhibition of CX3CL1 (fractalkine) improves experimental autoimmune myositis in SJL/J mice.

Suzuki F, Nanki T, Imai T, Kikuchi H, Hirohata S, Kohsaka H, Miyasaka N. Suzuki F, et al. Among authors: imai t. J Immunol. 2005 Nov 15;175(10):6987-96. doi: 10.4049/jimmunol.175.10.6987. J Immunol. 2005. PMID: 16272359

4

Chemokines as novel therapeutic targets for inflammatory bowel disease.

Nishimura M, Kuboi Y, Muramoto K, Kawano T, Imai T. Nishimura M, et al. Among authors: imai t. Ann N Y Acad Sci. 2009 Sep;1173:350-6. doi: 10.1111/j.1749-6632.2009.04738.x. Ann N Y Acad Sci. 2009. PMID: 19758172 Review.

5

Phase 1 study on the safety and efficacy of E6011, antifractalkine antibody, in patients with Crohn's disease.

Matsuoka K, Naganuma M, Hibi T, Tsubouchi H, Oketani K, Katsurabara T, Hojo S, Takenaka O, Kawano T, Imai T, Kanai T. Matsuoka K, et al. Among authors: imai t. J Gastroenterol Hepatol. 2021 Aug;36(8):2180-2186. doi: 10.1111/jgh.15463. Epub 2021 Mar 31. J Gastroenterol Hepatol. 2021. PMID: 33599356 Free PMC article. Clinical Trial.

6

Dual functions of fractalkine/CX3C ligand 1 in trafficking of perforin+/granzyme B+ cytotoxic effector lymphocytes that are defined by CX3CR1 expression.

Nishimura M, Umehara H, Nakayama T, Yoneda O, Hieshima K, Kakizaki M, Dohmae N, Yoshie O, Imai T. Nishimura M, et al. Among authors: imai t. J Immunol. 2002 Jun 15;168(12):6173-80. doi: 10.4049/jimmunol.168.12.6173. J Immunol. 2002. PMID: 12055230

7

Membrane-bound form of fractalkine induces IFN-gamma production by NK cells.

Yoneda O, Imai T, Nishimura M, Miyaji M, Mimori T, Okazaki T, Domae N, Fujimoto H, Minami Y, Kono T, Bloom ET, Umehara H. Yoneda O, et al. Among authors: imai t. Eur J Immunol. 2003 Jan;33(1):53-8. doi: 10.1002/immu.200390007. Eur J Immunol. 2003. PMID: 12594832 Free article.

8

Fractalkine in vascular biology: from basic research to clinical disease.

Umehara H, Bloom ET, Okazaki T, Nagano Y, Yoshie O, Imai T. Umehara H, et al. Among authors: imai t. Arterioscler Thromb Vasc Biol. 2004 Jan;24(1):34-40. doi: 10.1161/01.ATV.0000095360.62479.1F. Epub 2003 Sep 11. Arterioscler Thromb Vasc Biol. 2004. PMID: 12969992 Review.

9

Infiltration of CD8+ T cells containing RANTES/CCL5+ cytoplasmic granules in actively inflammatory lesions of human chronic gastritis.

Ohtani N, Ohtani H, Nakayama T, Naganuma H, Sato E, Imai T, Nagura H, Yoshie O. Ohtani N, et al. Among authors: imai t. Lab Invest. 2004 Mar;84(3):368-75. doi: 10.1038/labinvest.3700039. Lab Invest. 2004. PMID: 14704722 Free article.

10

Inhibition of fractalkine ameliorates murine collagen-induced arthritis.

Nanki T, Urasaki Y, Imai T, Nishimura M, Muramoto K, Kubota T, Miyasaka N. Nanki T, et al. Among authors: imai t. J Immunol. 2004 Dec 1;173(11):7010-6. doi: 10.4049/jimmunol.173.11.7010. J Immunol. 2004. PMID: 15557198

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,284 results

Search Page

Filters